Supporting Huntington's Disease Families Through the Ups and Downs of Clinical Trials

Area of Science:

• Neurodegenerative Diseases
• Clinical Research
• Patient Advocacy

Background:

• Recent years saw multiple Huntington's disease (HD) clinical trials halted, impacting the patient community.
• The reality of clinical research, where drug approval is rare, presents challenges for HD families.
• An expanding research pipeline necessitates better preparation and support for the HD community.

Purpose of the Study:

• To explore how the Huntington's disease community can navigate the complexities of clinical research.
• To identify key areas for supporting HD families throughout the research process.
• To foster collaboration between patient advocacy groups and pharmaceutical companies.

Main Methods:

• Discussions were held between the Huntington's Disease Society of America (HDSA) and the Huntington's Disease Coalition for Patient Engagement (HD-COPE).
• HD-COPE, a global group led by HDSA and the Huntington's Society of Canada (HSC), works with pharmaceutical companies to ensure patient voices are included in trial design.
• Key themes from these conversations were summarized to inform support strategies.

Main Results:

• The Huntington's disease community requires robust engagement strategies.
• Comprehensive support systems are crucial for families participating in clinical research.
• Targeted education initiatives are needed to prepare patients for research realities.

Conclusions:

• Effective support for the Huntington's disease community in clinical research hinges on three pillars: engagement, support, and education.
• Proactive strategies are essential to help HD families manage the challenges and uncertainties of research participation.
• Continued collaboration between patient advocacy groups and researchers can improve the clinical trial experience for all involved.